

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 0874)

## ANNOUNCEMENT

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “Company”) is informed that pursuant to the Certain Guidelines on Promoting the Development of the Healthcare Industry issued by the State Council on 14 October 2013, Guangzhou Pharmaceutical Holdings Limited (“GPHL”), the controlling shareholder of the Company, on 23 October 2013, announced at a media communication, that GPHL intended to invest RMB5 billion in expanding its healthcare business through establishments, joint ventures and mergers and acquisitions as well as cooperation. GPHL will focus on implementing six critical strategies including technology, service, philosophy, brand, management and human resource and expand the WangLaoJi Great Health segment of GPHL from its current manufacturing business into comprehensive healthcare business comprising manufacturing, medical treatment, health management and health preservation and retirement, and to establish the most unique and remarkable healthcare service system in China within three to five years.

This announcement is made pursuant to Rule 13.10(B) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board of

**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 23 October 2013

*As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Ms. Cheng Ning and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.*